Biopharma & Life Sciences

Enanta Pharmaceuticals Executive Compensation (FY25)

Name: Enanta Pharmaceuticals (ENTA) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

ENTA · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Jay Luly

Latest say-on-pay support

March 11, 2026

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The Enanta Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 6, 2026Latest filing (8-K): March 12, 2026

6 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Enanta Pharmaceuticals brief$500Get the executive brief

Velarion Intel, one year, every company

225 figures on this page: 223 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

This company is not required to report a chief executive pay ratio.

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive total compensation — Jay Luly: $2,695,276 → $2,769,548 (2.8% higher)

Frequently asked questions

Answers drawn from the data on this page.

Who is Enanta Pharmaceuticals' chief executive and what were they paid?

Jay Luly, President and Chief Executive Officer, received $2,769,548 in total compensation for fiscal 2025. Luly's total was 2.8% higher than the $2,695,276 reported for fiscal 2024.

What was Enanta Pharmaceuticals' say-on-pay result?

For fiscal 2025, the say-on-pay proposal drew 97.2% support at the meeting held March 11, 2026.

Which companies are in Enanta Pharmaceuticals' peer group?

The disclosed peer group names Allogene Therapeutics, Altimmune, Arcturus Therapeutics, Heron Therapeutics and Inovio Pharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jay Luly President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Scott Rottinghaus Chief Medical Officer	◇	◇	◇	◇	◇	—	◇	◇
Nathaniel Gardiner Chief Legal Officer and Corporate Secretary	◇	—	◇	◇	◇	—	◇	◇
Brendan Luu Chief Business Officer	◇	—	◇	◇	◇	—	◇	◇
Yat Sun Or Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Paul Mellett Chief Financial and Administrative Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jay Luly President and Chief Executive	◇	—	◇	◇	◇	—	◇	◇
Nathaniel Gardiner Chief Legal Officer and Corporate Secretary	◇	—	◇	◇	◇	—	◇	◇
Paul Mellett Chief Financial and	◇	—	◇	◇	◇	—	◇	◇
Brendan Luu Chief Business Officer	◇	—	◇	◇	◇	—	◇	◇
Yat Sun Or Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Scott Rottinghaus Chief Medical Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jay Luly President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Matthew Kowalsky Chief Legal Officer	◇	—	◇	◇	◇	—	◇	◇
Scott Rottinghaus Chief Medical Officer	◇	—	◇	◇	◇	—	◇	◇
Yat Sun Or Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Paul Mellett Chief Financial and Administrative Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jay Luly President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Scott Rottinghaus Chief Medical Officer	◇	—	◇	◇	◇	—	◇	◇
Yat Sun Or Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Jay Luly	OPTION	—	—	—	—	—	—	◇
Jay Luly	PSU	—	—	—	—	—	—	◇
Scott Rottinghaus	OPTION	—	—	—	—	—	—	◇
Scott Rottinghaus	PSU	—	—	—	—	—	—	◇
Yat Sun Or	PSU	—	—	—	—	—	—	◇
Yat Sun Or	OPTION	—	—	—	—	—	—	◇

Fiscal 2023, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Jay Luly	Option	◇	—	◇	11/27/2034
	Option	◇	—	◇	11/22/2033
	Option	◇	—	◇	11/23/2032
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	11/19/2031
	RSU	◇	◇	—	—
Yat Or	Option	◇	—	◇	11/27/2034
	Option	◇	—	◇	11/22/2033
	Option	◇	—	◇	11/23/2032
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	11/19/2031
	RSU	◇	◇	—	—
Scott Rottinghaus	Option	◇	—	◇	11/27/2034
	Option	◇	—	◇	11/22/2033
	Option	◇	—	◇	8/8/2032
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	11/23/2032
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Jay Luly

President and Chief Executive Officer · Severance agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Scott Rottinghaus

Chief Medical Officer · Severance agreement

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Yat Sun Or

Chief Scientific Officer · Employment agreement

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Bruce L.A. Carter, Ph.D Board chair	◇	—	◇	—	—	—	◇
Terry C. Vance	◇	—	◇	—	—	—	◇
Mark G. Foletta	◇	—	◇	—	—	—	◇
Kristine Peterson	◇	—	◇	—	—	—	◇
Lesley Russell, MBChB, MRCP	◇	—	◇	—	—	—	◇
Yujiro Hata	◇	—	◇	—	—	—	◇

Jay R. Luly, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Stock Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Allogene Therapeutics ALLO
Altimmune ALT
Arcturus Therapeutics ARCT
Heron Therapeutics HRTX
Inovio Pharmaceuticals INO
Karyopharm Therapeutics KPTI
Lexicon Pharmaceuticals LXRX
Nektar Therapeutics NKTR
Rigel Pharmaceuticals RIGL
Sage Therapeutics SAGE
Travere Therapeutics TVTX
Vanda Pharmaceuticals VNDA

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	March 11, 2026	=	◇	◇	◇
2024	March 13, 2025	=	◇	◇	◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Jay Luly (President and Chief Executive Officer), FY2025 total compensation $2,769,548 (base salary $803,300) [exec_comp, SEC accession 0001193125-26-022558, filed 2026-01-26]

See a complete sample report

What this page does not include

Everything above is a fact Enanta Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Enanta Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

225 figures on this page: 223 cited to the filing that reported them, 2 calculated from figures it prints.

223 cited to the filing

2 calculated from the filing

Documents cited

8-K, filed March 12, 2026
0001193125-26-104109
Proposal No. 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers.
DEF 14A, filed January 26, 2026
0001193125-26-022558
DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal 2025 Year-End · Summary Compensation Table
Filing, filed January 26, 2026
8-K, filed March 17, 2025
0000950170-25-040230
Proposal No. 4: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers.
DEF 14A, filed January 27, 2025
0000950170-25-009168
Summary Compensation Table
DEF 14A, filed January 26, 2024
0000950170-24-007956
Summary Compensation Table

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Enanta Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ENTA (accessed 2026).

Short form: data: Velarion

The Enanta Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

6 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/ENTA/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Enanta Pharmaceuticals executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Enanta Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers Enanta Pharmaceuticals discloses

The companies named in ENTA's own disclosed peer group.

Allogene Therapeutics Altimmune Arcturus Therapeutics Heron Therapeutics Inovio Pharmaceuticals Karyopharm Therapeutics Lexicon Pharmaceuticals Nektar Therapeutics Rigel Pharmaceuticals Sage Therapeutics Travere Therapeutics Vanda Pharmaceuticals

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}